| Authors | Kean, J.D. Sarris, J. Scholey, A. Silberstein, R. Downey, L.A. Stough, C. |
|---|---|
| Type | Journal Article (Original Research) |
| Journal | Psychopharmacology |
| PubMed ID | 27921139 |
| Year of Publication | 2017 |
| URL | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5225177/ |
| DOI | http://dx.doi.org/10.1186/s12890-015-0082-310.1007/s00213-016-4471-y |
| Download |  213_2016_Article_4471.pdf (540.6 KB) |
| Abstract | INTRODUCTION: This study investigated the effects of a marine oil extract (PCSO-524®) on inattention, hyperactivity, mood and cognition in children and adolescents. PCSO-524® is a standardised lipid extract of the New Zealand green-lipped mussel and is an inflammatory modulator that inhibits the 5′-lipoxygenase and cyclooxygenase pathways and decreases concentrations of the pro-inflammatory arachidonic acid (AA). METHODS: PCSO-524® or a matched placebo was administered for 14 weeks to 144 participants (123 males/21 females; mean age 8.7 years) with high hyperactivity and inattention in a randomised, double-blind, placebo-controlled study. The primary outcome was the Conners Parent Rating Scale assessing parental reports of behavioural problems. Secondary outcomes assessed changes in cognition and mood. RESULTS: The results of the present study did not support the hypothesis that PCSO-524® improves parental reports of hyperactivity, inattention and impulsivity in children ages 6 to 14 years over placebo. Repeated measures ANOVA on post hoc subsample analysis indicated significant improvements in hyperactivity (p = 0.04), attention (p = 0.02), learning (p = 0.05) and probability of ADHD (p = 0.04) with a medium to large average effect size (d = 0.65) in those children who did not meet criteria for combined hyperactivity and inattention. Furthermore, significant improvements in the PCSO-524® group were indicated in a whole sample repeated measures ANCOVA on recognition memory between baseline and week 8 over placebo (p = 0.02, d = 0.56); this difference was not sustained at week 14. CONCLUSIONS: The results presented indicate that PCSO-524® may be beneficial in reducing levels of hyperactivity and inattention in a population of children with clinical and subclinical symptoms of ADHD. |
http://www.ibas.org.au/what-we-do/publications/3872910
Sleep apnea is a condition where breathing is abnormal during sleep. There are two main forms of sleep apnea: obstructive and central. For obstructive sleep apnea, breathing is reduced because the airway...
Each year in Australia 260 people sustain a SCI, with over half losing full function in their arms and legs (quadriplegia). In addition to the primary disability, there is a very high rate of Obstructive...
NTC RELEASES 'WORLD FIRST' HEAVY VEHICLE DRIVER FATIGUE STUDY
The National Transport Commission (NTC) and the Cooperative Research Centre for Alertness, Safety and Productivity (Alertness CRC) have released the results of what is hailed as a world-first study into heavy vehicle driver fatigue.
AAMRI ELECTION STATEMENT RELEASED ON 25TH MARCH 2019
AAMRI released its election statement calling on politicians to commit to three main priorities: ensuring the MRFF reaches $20 billion by 2020-21, provide continued strong support for the NHMRC, and develop sustainable and rewarding career pathways.
IBAS DIRECTOR ANNA BURKE UNVEILS HER PORTRAIT AT CANBERRA'S PARLIAMENT HOUSE
Anna Burke had barely got into the swing of her speech at the unveiling of her portrait at Canberra's Parliament House when the ringing of bells caused half her audience to hurry away
NATIONAL STUDY OFFERS HOPE FOR BREATHLESSNESS
A national medication study is aiming to help thousands of Australians who struggle every day with shortness of breath
© 2019 Institute for Breathing and Sleep. All Rights Reserved.
Powered by Helmut Design | Manage
